Astex Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Astex Pharmaceuticals Ltd.
After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.
A couple of trials for two investigational late-stage breast cancer candidates from AstraZeneca have each produced encouraging data for a novel drug class where rivals have previously hit clinical buffers.
Francis Bouchard, Region Head for AMACO (Asia Pacific, Middle East and Africa Countries), Novartis Oncology, discusses a range of issues around mainstreaming personalized/precision oncology therapies such as Kymriah in the region, including reimbursement systems, partnerships and digital initiatives.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.